Analysts on Wall Street have recently re-evaluated their perspectives on several prominent companies, leading to new ratings and price targets. This report highlights key initiations, including a bearish outlook for Target Corporation, alongside positive coverage for Abercrombie & Fitch, AeroVironment, Tower Semiconductor, and ResMed. These shifts reflect the dynamic nature of market sentiment and expert expectations for these corporations.

Analyst Initiations: Bearish Outlook for Target Amidst Bullish Calls for Others

On September 18, 2025, several top Wall Street analysts released new coverage and updated price targets for a range of companies, impacting investor sentiment. Most notably, Spencer Hanus, an analyst from Wolfe Research, initiated coverage on Target Corporation (TGT) with an 'Underperform' rating and set a price target of $80. This move signals a cautious or negative outlook on the retail giant's future performance. Target shares had closed at $88.93 on the preceding Wednesday, making this initiation particularly noteworthy for potential investors.

Conversely, other companies received more favorable initiations. Janine Stichter of BTIG began coverage on Abercrombie & Fitch Co. (ANF) with a 'Buy' rating and a price target of $120. Abercrombie & Fitch's shares had closed at $85.39 on Wednesday, indicating a significant potential upside according to BTIG. In the aerospace and defense sector, Ronald Epstein from B of A Securities initiated coverage on AeroVironment, Inc. (AVAV) with a 'Buy' rating and a price target of $300. AeroVironment had closed at $272.07, suggesting a positive outlook for the company.

Furthermore, the semiconductor industry saw new coverage for Tower Semiconductor Ltd. (TSEM) from Barclays' analyst Tavy Rosner, who issued an 'Equal-Weight' rating with a price target of $74. Tower Semiconductor shares were trading at $67.80 at Wednesday's close. Lastly, Laura Sutcliffe of Citigroup initiated coverage on ResMed Inc. (RMD), a medical device company, with a 'Buy' rating and an ambitious price target of $330. ResMed's closing price on Wednesday was $271.71, implying strong growth potential.

These analyst initiations provide valuable insights for investors, highlighting varying expert opinions on the market's leading companies. While Target faces a new bearish sentiment, other firms like Abercrombie & Fitch, AeroVironment, and ResMed have garnered bullish attention, showcasing the diverse opportunities and risks present in the current investment landscape.

The latest analyst ratings underscore the importance of thorough research and diverse perspectives when evaluating investment opportunities. The varied outlooks, particularly the 'Underperform' rating for Target, serve as a reminder that even established companies can face skepticism from financial experts. For investors, these initiations are crucial data points, encouraging a deeper dive into the fundamental factors driving these evaluations and prompting a critical assessment of their own portfolios. It highlights that market sentiment is not monolithic, and a balanced approach, considering both bullish and bearish cases, is essential for informed decision-making.